Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine versus metoclopramide for gastric residual volume in mechanically ventilated ICU patients
IRCT20190804044432N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of neostigmine and metoclopramide in enteral feeding intolerance (EFI) (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoint: gastric residual volume. Started Sep 2019; status: completed.
02
Drugs
neostigminemetoclopramide
03
Conditions
enteral feeding intolerance (EFI)
Beyond the preview
Go deeper on IRCT20190804044432N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190804044432N1.